to-BBB technologies BV - Product Pipeline Review - 2014

Published: Aug, 2014 | Pages: 30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

to-BBB technologies BV - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'to-BBB technologies BV - Product Pipeline Review - 2014', provides an overview of the to-BBB technologies BV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of to-BBB technologies BV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of to-BBB technologies BV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of to-BBB technologies BV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the to-BBB technologies BV's pipeline products

Reasons to buy

- Evaluate to-BBB technologies BV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of to-BBB technologies BV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the to-BBB technologies BV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of to-BBB technologies BV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of to-BBB technologies BV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of to-BBB technologies BV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
to-BBB technologies BV Snapshot 4
to-BBB technologies BV Overview 4
Key Information 4
Key Facts 4
to-BBB technologies BV - Research and Development Overview 5
Key Therapeutic Areas 5
to-BBB technologies BV - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
to-BBB technologies BV - Pipeline Products Glance 12
to-BBB technologies BV - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
to-BBB technologies BV - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
to-BBB technologies BV - Drug Profiles 16
2B3-101 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
2B3-201 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecules for Inherited Retinal Diseases 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
2B3-XXX 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
to-BBB technologies BV - Pipeline Analysis 22
to-BBB technologies BV - Pipeline Products by Target 22
to-BBB technologies BV - Pipeline Products by Route of Administration 23
to-BBB technologies BV - Pipeline Products by Molecule Type 24
to-BBB technologies BV - Pipeline Products by Mechanism of Action 25
to-BBB technologies BV - Recent Pipeline Updates 26
to-BBB technologies BV - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
to-BBB technologies BV, Key Information 4
to-BBB technologies BV, Key Facts 4
to-BBB technologies BV - Pipeline by Indication, 2014 7
to-BBB technologies BV - Pipeline by Stage of Development, 2014 8
to-BBB technologies BV - Monotherapy Products in Pipeline, 2014 9
to-BBB technologies BV - Partnered Products in Pipeline, 2014 10
to-BBB technologies BV - Partnered Products/ Combination Treatment Modalities, 2014 11
to-BBB technologies BV - Phase II, 2014 12
to-BBB technologies BV - Phase I, 2014 13
to-BBB technologies BV - Preclinical, 2014 14
to-BBB technologies BV - Discovery, 2014 15
to-BBB technologies BV - Pipeline by Target, 2014 22
to-BBB technologies BV - Pipeline by Route of Administration, 2014 23
to-BBB technologies BV - Pipeline by Molecule Type, 2014 24
to-BBB technologies BV - Pipeline Products by Mechanism of Action, 2014 25
to-BBB technologies BV - Recent Pipeline Updates, 2014 26
to-BBB technologies BV, Subsidiaries 28